logo

Clinical Trial Calendar

Share SHARE
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q4 2017
Vical Inc.
Topline data from phase 3 trial of ASP0113 CMV Vaccine
Prevent cytomegalovirus in subjects undergoing allogeneic hematopoietic stem cell transplant
Q4 2017
StemCells Inc
Results from phase 2 study of HuCNS-SC (Pathway Study)
Cervical spinal cord injury (cSCI)
Q4 2017
EYEGATE PHARMACEUTICALS INC
Topline data from confirmatory Phase 3 trial of EGP-437 combination product
Non-infectious anterior uveitis;
Q4 2017
Aquinox Pharmaceuticals, Inc.
Top-line data from first Phase 3 trial of AQX-1125
Interstitial cystitis/bladder pain syndrome
Q4 2017
Arena Pharmaceutical Inc.
Data from phase 2 study of Etrasimod
ulcerative colitis
Q4 2017
Audentes Therapeutics, Inc.
Data from Phase 1/2 study of AT132 (ASPIRO)
X-Linked Myotubular Myopathy
Q4 2017
Aquinox Pharmaceuticals, Inc.
Topline data from phase 3 trial of AQX-1125 (LEADERSHIP 301)
interstitial cystitis/bladder pain syndrome
Q4 2017
Aimmune Therapeutics Inc.
Topline results from phase 3 study of AR101 (PALISADE)
Peanut Allergy
Q4 2017
CAPRICOR THERAPEUTICS, INC.
12-month data from phase II trial of CAP-1002 (ALLSTAR)
cardiac dysfunction, following a large heart attack
Q4 2017
Revance Therapeutics, Inc.
Topline data from phase 3 program of DaxibotulinumtoxinA (SAKURA)
moderate to severe glabellar lines in adults.
Q4 2017
CymaBay Therapeutics Inc.
Phase 2 data of Seladelpar (25 mg)
primary biliary cholangitis
Q4 2017
Galapagos NV..
Top line data from phase IIa study of GLPG2222 (ALBATROSS)
cystic fibrosis harboring one F508del CFTR mutation and one gating mutation.
Q4 2017
Revance Therapeutics, Inc.
Results from phase 2 study of RT002
plantar fasciitis.
Q4 2017
Regulus Therapeutics Inc.
Data from Phase I/II renal biopsy study i
Alport syndrome
Q4 2017
Axsome Therapeutics, Inc.
Interim analysis results from phase 3 trial of AXS-02 ( CREATE-1 )
Complex Regional Pain Syndrome
Q4 2017
Esperion Therapeutics
Top line results from phase 2 study of triplet oral therapy
hypercholesterolemia
Q4 2017
Corbus Pharmaceuticals Holdings, Inc.
Top line data from phase 2 study of Anabasum
skin-predominant dermatomyositis
Late 2017
AcelRx Pharmaceuticals Inc.
Resubmission of ZALVISO NDA
management of moderate-to-severe acute pain in adult patients in the hospital setting
Late 2017
Otonomy Inc.
Topline data from phase 3 study of OTIVIDEX (AVERTS-2)
Ménière’s disease
Late 2017
Agios Pharmaceuticals, Inc.
Submit NDA for Ivosidenib
IDH1m positive Relapsed and Refractory Acute Myeloid Leukemia
Late 2017
Pfizer Inc.
Data from phase 3 trial of XTANDI (PROSPER)
Patients with non-metastatic Castration-Resistant Prostate Cancer
Late 2017
Regenxbio Inc
Interim results from phase I/II trial of RGX-501
homozygous familial hypercholesterolemia
Late 2017
Bellerophon Therapeutics LLC
Top line results from phase 3 study of INOpulse
Pulmonary Arterial Hypertension
Late 2017
CONCERT PHARMACEUTICALS, INC.
Top line data from Phase 2a trial of CTP-543
moderate-to-severe alopecia areata
Late 2017
CONCERT PHARMACEUTICALS, INC.
Top line data from Phase 2 trial of CTP-656 i
Cystic Fibrosis